Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.

导出 LinkOut

翻译打印收藏纠错

作者： Keita,Izumi ^[1] ; Masaharu,Inoue ^[2] ; Satoshi,Washino ^[3] ; Suguru,Shirotake ^[1] ; Makoto,Kagawa ^[3] ; Hideki,Takeshita ^[3] ; Yuji,Miura ^[4] ; Yoji,Hyodo ^[3] ; Masafumi,Oyama ^[5] ; Satoru,Kawakami ^[3] ; Tomoaki,Miyagawa ^[6] ; Kazutaka,Saito ^[3] ; Yukio,Kageyama ^[6]

作者单位： Department of Urology, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan. ^[1] Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan. ^[2] Musashino Study Group, Saitama, Japan. ^[3] Department of Urology, Jichi Medical University Saitama Medical Center, Omiya-ku, Saitama, Japan. ^[4] Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. ^[5] Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan. ^[6] Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan. ^[7]

关键词 immune checkpoint inhibitor ipilimumab metastatic renal cell carcinoma nivolumab non-clear cell renal cell carcinoma

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 肾细胞(Carcinoma, Renal Cell);肾肿瘤(Kidney Neoplasms);回顾性研究(Retrospective Studies)

DOI 10.1111/iju.15128

PMID 36541136

发布时间 2023-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交